Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study

Overview

Journal Am J Alzheimers Dis Other Demen

Publisher Sage Publications

Specialty Neurology

Date 2020 Feb 14

PMID 32052640

Citations 10

Authors

Taisei Wake

Hajime Tabuchi

Kei Funaki

Daisuke Ito

Bun Yamagata

Takahito Yoshizaki

Tadaki Nakahara

Masahiro Jinzaki

Haruo Yoshimasu

Iori Tanahashi

Hiroumi Shimazaki

Masaru Mimura

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive ( = 10) or amyloid-negative ( = 32) groups. We assessed symptoms of anxiety, depression, and test-related distress at 6, 24, and 52 weeks after results disclosure. No difference was found over time in anxiety, depression, and test-related distress in either group. Although no significant differences were observed between groups in anxiety or depression, the amyloid-negative group had a significantly higher level of test-related distress than the amyloid-positive group at 52 weeks. Disclosing amyloid status to cognitively healthy research participants with SCD did not cause significant long-term psychological risks. However, a theoretical spectrum of subjective concern may exist about cognitive decline in amyloid-negative individuals.

Citing Articles

Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review.

Perry J, Radenbach K, Geschke K, Rostamzadeh A Alzheimers Dement. 2024; 20(12):8910-8936.

PMID: 39559917 PMC: 11667511. DOI: 10.1002/alz.14365.

Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.

Hendriksen H, de Rijke T, Fruijtier A, van de Giessen E, Van Harten A, van Leeuwenstijn-Koopman M Alzheimers Dement. 2024; 20(9):6556-6565.

PMID: 39087383 PMC: 11497681. DOI: 10.1002/alz.14148.

Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson's Disease: A Narrative Review.

Schaeffer E, Yilmaz R, St Louis E, Noyce A J Parkinsons Dis. 2024; 14(s2):S307-S319.

PMID: 38995800 PMC: 11492008. DOI: 10.3233/JPD-230428.

Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial.

Grill J, Raman R, Ernstrom K, Wang S, Donohue M, Aisen P Neurol Clin Pract. 2024; 14(2):e200265.

PMID: 38585443 PMC: 10996909. DOI: 10.1212/CPJ.0000000000200265.

Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.

Rahman-Filipiak A, Bolton C, Grill J, Rostamzadeh A, Chin N, Heidebrink J Alzheimers Dement. 2023; 19(9):4270-4275.

PMID: 37450489 PMC: 10530125. DOI: 10.1002/alz.13380.

References

Jessen F, Amariglio R, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6):844-52. PMC: 4317324. DOI: 10.1016/j.jalz.2014.01.001. View

Burns J, Johnson D, Liebmann E, Bothwell R, Morris J, Vidoni E . Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017; 13(9):1024-1030. PMC: 5582024. DOI: 10.1016/j.jalz.2017.01.022. View

Slot R, Sikkes S, Berkhof J, Brodaty H, Buckley R, Cavedo E . Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimers Dement. 2018; 15(3):465-476. PMC: 6465066. DOI: 10.1016/j.jalz.2018.10.003. View

Perrotin A, Mormino E, Madison C, Hayenga A, Jagust W . Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012; 69(2):223-9. PMC: 4004919. DOI: 10.1001/archneurol.2011.666. View

Cantegreil-Kallen I, Pin S . Fear of Alzheimer's disease in the French population: impact of age and proximity to the disease. Int Psychogeriatr. 2011; 24(1):108-16. DOI: 10.1017/S1041610211001529. View

Koike A, Sugishita M . [The Japanese version of the Wechsler Memory Scale--revised]. Nihon Rinsho. 2012; 69 Suppl 8:408-12. View

Kotov R, Gamez W, Schmidt F, Watson D . Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. Psychol Bull. 2010; 136(5):768-821. DOI: 10.1037/a0020327. View

Molinuevo J, Rabin L, Amariglio R, Buckley R, Dubois B, Ellis K . Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2016; 13(3):296-311. PMC: 5344703. DOI: 10.1016/j.jalz.2016.09.012. View

Snitz B, Weissfeld L, Cohen A, Lopez O, Nebes R, Aizenstein H . Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. Am J Geriatr Psychiatry. 2015; 23(9):985-93. PMC: 4532656. DOI: 10.1016/j.jagp.2015.01.008. View

10.

Scheef L, Spottke A, Daerr M, Joe A, Striepens N, Kolsch H . Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012; 79(13):1332-9. DOI: 10.1212/WNL.0b013e31826c1a8d. View

11.

Steinberg S, Negash S, Sammel M, Bogner H, Harel B, Livney M . Subjective memory complaints, cognitive performance, and psychological factors in healthy older adults. Am J Alzheimers Dis Other Demen. 2013; 28(8):776-83. PMC: 4617766. DOI: 10.1177/1533317513504817. View

12.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

13.

Perrotin A, La Joie R, De La Sayette V, Barre L, Mezenge F, Mutlu J . Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates. Alzheimers Dement. 2016; 13(5):550-560. DOI: 10.1016/j.jalz.2016.08.011. View

14.

Asukai N, Kato H, Kawamura N, Kim Y, Yamamoto K, Kishimoto J . Reliability and validity of the Japanese-language version of the impact of event scale-revised (IES-R-J): four studies of different traumatic events. J Nerv Ment Dis. 2002; 190(3):175-82. DOI: 10.1097/00005053-200203000-00006. View

15.

Roberts J, Dunn L, Rabinovici G . Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag. 2015; 3(3):219-229. PMC: 4498486. DOI: 10.2217/nmt.13.25. View

16.

Kessler E, Bowen C, Baer M, Froelich L, Wahl H . Dementia worry: a psychological examination of an unexplored phenomenon. Eur J Ageing. 2017; 9(4):275-284. PMC: 5549110. DOI: 10.1007/s10433-012-0242-8. View

17.

Studer J, Donati A, Popp J, von Gunten A . Subjective cognitive decline in patients with mild cognitive impairment and healthy older adults: association with personality traits. Geriatr Gerontol Int. 2013; 14(3):589-95. DOI: 10.1111/ggi.12139. View

18.

Verfaillie S, Tijms B, Versteeg A, Benedictus M, Bouwman F, Scheltens P . Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimers Dement (Amst). 2017; 5:43-52. PMC: 5198882. DOI: 10.1016/j.dadm.2016.10.007. View

19.

Arnau R, Meagher M, Norris M, Bramson R . Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients. Health Psychol. 2001; 20(2):112-9. DOI: 10.1037//0278-6133.20.2.112. View

20.

Lim Y, Maruff P, Getter C, Snyder P . Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. Alzheimers Dement. 2016; 12(4):454-8. DOI: 10.1016/j.jalz.2015.09.005. View